[CLSTR]
< Back to situation

[REVISION HISTORY]

CVM mandates Centaurus tender offer for Oncoclínicas

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-26 11:15 UTC → 2026-08-27 01:33 UTC · added removed

The Brazilian Securities and Exchange Commission (CVM) has unanimously decided that Centaurus Capital must launch approved a mandatory public tender offer (OPA) for shares of Oncoclínicas (ONCO3). This ruling reverses Oncoclínicas. In a 3-0 vote, the previous stance of CVM board reversed the CVM’s recommendation of its technical department, which had previously argued that the November 2024 reorganization of the Josephina funds did not trigger necessitate a new acquisition. The CVM board’s decision supports the claims made mandate follows a dispute led by minority shareholders, led by including Latache Capital, who argued that the reorganization triggered a ‘poison pill’ clause in the company’s bylaws. This clause mandates requires a tender offer if an investor’s stake exceeds 15%. The dispute centered on reorganization resulted in the Josephina III fund, a vehicle linked to Centaurus, which ended up directly Centaurus Capital, holding a 31.83% stake in Oncoclínicas. Centaurus Capital continues to contest the decision, ruling, maintaining that its economic interest in the company predates the IPO and that the reorganization was merely a structural change in ownership rather than a new acquisition. In response, Centaurus has initiated arbitration through the B3 Arbitration Chamber. Additionally, Chamber (CAM), arguing that the Brazilian Association chamber holds exclusive jurisdiction over commercial disputes between shareholders. The CVM has stipulated that the tender offer must be executed within 60 days of Investment, Credit, August 25. However, several critical details remain unresolved, including the final offer price, the specific payer, and Consumption (Abraicc) has announced its intention to file a lawsuit to enforce the mandated offer. exact eligibility of shareholders. Following the announcement of the CVM’s decision, Oncoclínicas shares experienced a significant increase.

Versions

  1. 2026-08-27 01:33 UTC CVM mandates Centaurus tender offer for Oncoclínicas
  2. 2026-08-26 11:15 UTC CVM mandates Centaurus tender offer for Oncoclínicas
  3. 2026-08-25 23:15 UTC Oncoclínicas mandatory tender offer dispute
  4. 2026-08-25 00:34 UTC Oncoclínicas mandatory tender offer dispute

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.